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We tested the ﬂ  uoroquinolone susceptibility of 499 Sal-
monella enterica isolates collected from travelers returning 
to Finland during 2003–2007. Among isolates from travelers 
to Thailand and Malaysia, reduced ﬂ  uoroquinolone suscep-
tibility decreased from 65% to 22% (p = 0.002). All isolates 
showing nonclassical quinolone resistance were from trav-
elers to these 2 countries.    
F
luoroquinolones are the most commonly used anti-
microbial agents for the treatment of salmonellosis in 
adult patients (1). The proportion of nontyphoidal strains of 
Salmonella enterica with reduced ﬂ  uoroquinolone suscep-
tibility has increased during recent years in many countries 
(1–3). In Finland, ﬂ  uoroquinolone susceptibility of salmo-
nella has been surveyed since 1995 by analyzing isolates 
from patients who acquired the disease either at home or 
abroad. From 1995 through 2004, reduced ﬂ  uoroquinolone 
susceptibility (MIC >0.125 μg/mL) increased signiﬁ  cantly 
(4.0% to 39%) among all foreign Salmonella isolates (3,4). 
The increase was most prominent among isolates from 
Southeast Asia, especially Thailand (4). 
Until 2002, all Salmonella isolates worldwide with re-
duced ciproﬂ  oxacin susceptibility were uniformly resistant 
to nalidixic acid (3–5); i.e., they exhibited the conventional 
quinolone resistance phenotype. In 2003, we identiﬁ  ed Sal-
monella isolates that showed reduced susceptibility to cip-
roﬂ  oxacin but were either susceptible (MIC <32 μg/mL) 
or only low-level resistant (MIC = 32 μg/mL) to nalidixic 
acid. All Salmonella isolates with this nonclassical qui-
nolone resistance phenotype were from travelers returning 
from Thailand or Malaysia (6). We undertook this study 
to survey the recent incidence of reduced ﬂ  uoroquinolone 
susceptibility among nontyphoidal strains of S. enterica ac-
quired by Finnish travelers abroad and to deﬁ  ne the epide-
miology of the nonclassical quinolone-resistant Salmonella 
population.  
The Study
Our study included 499 S. enterica isolates collected 
during 2003–2007 from Finnish travelers returning from 
abroad; due to a technical error, in 2004 only 99 foreign 
Salmonella isolates were sent to us from the National Sal-
monella Reference Center. The ﬁ  rst 100 foreign Salmo-
nella isolates identiﬁ  ed during January of each year were 
collected. An isolate was designated to be of foreign origin 
if the patient had reported travel abroad during the month 
before the specimen was obtained. Epidemiologic infor-
mation regarding travel destination was collected from the 
forms accompanying each isolate. 
MICs of ciproﬂ  oxacin and nalidixic acid for the iso-
lates were determined by using plate agar dilution (7). 
The MIC breakpoint value for reduced ciproﬂ  oxacin sus-
ceptibility was chosen as >0.125 μg/mL on the basis of 
earlier publications (4,5,8). The breakpoints for nalidixic 
acid were 16 μg/mL for susceptibility and 32 μg/mL for 
resistance, according to Clinical and Laboratory Standards 
Institute guidelines (7).
Pulsed-ﬁ  eld gel electrophoresis (PFGE) was performed 
using PulseNet standardized protocol with few modiﬁ  ca-
tions (9). We considered any difference between 2 proﬁ  les 
to be sufﬁ  cient to distinguish 2 different PFGE proﬁ  les. 
Data concerning the number of travelers from Fin-
land to countries of interest (i.e., countries with Salmonel-
la isolates showing reduced ﬂ  uoroquinolone susceptibil-
ity) during the study months were received from Statistics 
Finland (www.stat.ﬁ  ). Susceptibility data were analyzed 
by using WHONET5.4. For statistical analyses, we sum-
marized data on the basis of the number and proportion 
of Salmonella isolates with reduced ﬂ  uoroquinolone sus-
ceptibiity. The trend over years was analyzed using a lo-
gistic regression model with year as a covariate; p<0.05 
was considered signiﬁ  cant. Statistical analyses were per-
formed using SAS for Windows version 9.1.3 (SAS Insti-
tute Inc., Cary, NC, USA).       
Of the 499 S. enterica isolates collected, 227 came from 
travelers returning to Finland from Thailand or Malaysia 
(Table). Among all Salmonella isolates, reduced ﬂ  uoroqui-
nolone susceptibility decreased from 48% in 2003 to 34% 
in 2007 (p = 0.029). Among the isolates from Thailand and 
Malaysia, the decrease was 65% to 32% (p = 0.002) (Fig-
ure 1, panel A). However, when excluding isolates from 
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ceptibility remained fairly stable from 2003 to 2007 (31% 
vs. 37%; p = 0.787). 
Among all Salmonella isolates, conventional quinolo-
ne resistance decreased signiﬁ  cantly during the study, from 
39% in 2003 to 22% in 2007 (p = 0.012). This decrease was 
even more conspicuous among isolates from Thailand and 
Malaysia (47% vs. 12%; p = 0.0014) (Figure 1, panel B). 
The nonclassical quinolone resistance phenotype ﬁ  rst 
appeared in 2003. Subsequently, 36 Salmonella isolates 
showing this resistance pattern have been identiﬁ  ed. From 
2003 through 2007, the yearly proportions of Salmonella 
isolates showing the nonclassical quinolone resistance 
phenotype were 9%, 8%, 2%, 5%, and 12%, respectively; 
there was no signiﬁ  cant difference from year to year (p = 
0.720). Among the isolates from Thailand and Malaysia, 
the nonclassical quinolone resistance varied; however, the 
difference from year to year was not signiﬁ  cant (p = 0.878) 
(Figure 1, panel B). 
The 499 Salmonella isolates in this study were col-
lected from travelers returning from 43 different countries; 
isolates with reduced ciproﬂ  oxacin susceptibility were col-
lected from travelers returning from 18 countries (Table). 
All 36 isolates showing the nonclassical resistance pheno-
type were from Thailand or Malaysia; 47% of the isolates 
showing the conventional quinolone resistance phenotype 
were from these 2 countries.
The nonclassical quinolone resistance phenotype was 
found in 7 different serovars, of which S. enterica serovar 
Corvallis and S. enterica serovar Stanley were the most 
prevalent; among the conventional quinolone resistance 
phenotype,  S.  enteritidis  and  S.  virchow were the most 
prevalent. The 36 isolates belonging to the nonclassical 
phenotype were distinguished by PFGE to 16 different 
PFGE patterns (Figure 2). 
Conclusions
Reduced ﬂ  uoroquinolone susceptibility among nonty-
phoidal strains of S. enterica among travelers from Finland, 
as a whole, decreased signiﬁ  cantly during the study period, 
2003–2007 after having constantly increased for several 
DISPATCHES
810  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 5, May 2009
Figure 1. Ciproﬂ  oxacin susceptibility and quinolone resistance in 
227 Salmonella enterica isolates collected from travelers returning 
to Finland from Thailand or Malaysia, 2003–2007. A) Percentage 
of isolates showing reduced ciproﬂ  oxacin susceptibility (black bars, 
MIC >0.125 μg/mL, p = 0.002). B) Percentage of isolates showing 
conventional (black bars, MIC of nalidixic acid >32 μg/mL, p = 
0.0014) or nonclassical (white bars, MIC of nalidixic acid <32 μg/
mL, p = 0.878) quinolone resistance phenotype.
Table. Quinolone susceptibility of 499 Salmonella isolates collected from travelers returning to Finland, by country visited, 20032007* 
Country visited 
No. (%) 
isolates
No. isolates with CIP 
MIC >0.125 μg/mL 
No. isolates with NAL 
MIC >32 μg/mL 
No. isolates with NAL 
MIC <32 μg/mL 
No. trips from Finland 
during study months† 
Thailand‡ 212 (42.5) 98 67 31 122,472
Spain§ 66 (13.2) 25 25 0 426,822
Brazil 41 (8.2) 0 0 0 25,009
Egypt 40 (8.0) 17 17 0 47,291
India 32 (6.4) 7 7 0 26,233
Malaysia 15 (3.0) 6 1 5 2,597
Vietnam 9 (1.8) 2 2 0 7,555
Tanzania 9 (1.8) 2 2 0 1,259
Portugal 8 (1.6) 7 7 0 35,899
Morocco 5 (1.0) 3 3 0 8,708
Other areas  62 (12.4)  14 14 0
Total 499 (100)  181 145 36
*CIP, ciprofloxacin; NAL, nalidixic acid. 
†Data collected from statistics reports, Finland, based on the no. of Finnish travelers to these countries. 
‡No. Finnish travelers to Thailand from 2003 to 2007: 21,873; 22,882; 17,661; 21,941; and 38,115, respectively. 
§Includes Canary Islands. Fluoroquinolone Susceptibility in S. enterica 
years (3,4). The signiﬁ  cant decrease (p = 0.029) from 2003 
to 2007 was driven by isolates from Southeast Asia; the 
proportion of resistant strains from the other travel destina-
tions remained fairly stable. Notably, this recent decreasing 
trend in resistance was not linked with reduced travel to 
Thailand, as the number of  tourists from Finland going to 
Thailand more than doubled from 2005 to 2007 (Table).
In addition, after the emergence of the nonclassi-
cal quinolone resistance phenotype among S. enterica in 
Thailand and Malaysia, these isolates have persisted in that 
area. Our study shows a minor variation in the proportion 
of this resistance phenotype among the whole quinolone-
resistant population. For example, in 2005 the proportion 
of the nonclassical phenotype isolates was only 6%, but in 
that year, the proportion of all isolates with reduced cipro-
ﬂ  oxacin susceptibility was small. This result is most likely 
due to the collection of the foreign isolates soon after the 
tsunami catastrophe in December 2004; travelers from Fin-
land took >20% fewer trips to Thailand in 2005 than in 
2004 (Table).  
All of the Salmonella isolates showing the nonclassi-
cal quinolone resistance phenotype were from Thailand or 
Malaysia. Despite this geographic stability, isolates of the 
nonclassical phenotype were nonclonal, as shown by PFGE. 
These ﬁ  ndings provoke the question of whether the emer-
gence, persistence, and conﬁ  nement of those isolates in this 
area might have something to do with the living conditions 
of the residing population. In 2007, the proportion of the 
nonclassical phenotype surpassed that of the conventional 
phenotype for the ﬁ  rst time (20% vs. 12%; Figure 1, panel 
B). This increase in nonclassical phenotypes may be an 
emerging trend that needs to be under close surveillance. 
The nonclassical quinolone-resistant population may 
prove hard to identify in those microbiological laborato-
ries that use only nalidixic acid to screen for reduced ﬂ  uo-
roquinolone susceptibility in salmonella isolates. It is to 
be expected that this screening approach may fail due to 
susceptibility or only low-level resistance to nalidixic acid 
in these isolates (10–12). Isolates collected from travelers 
returning from Thailand or Malaysia should especially be 
examined for ﬂ  uoroquinolone susceptibility because nali-
dixic acid screening test results may no longer be predic-
tive of ﬂ  uoroquinolone resistance. At the present time, the 
nonclassical phenotype appears to be mainly conﬁ  ned to 
Thailand and Malaysia (10,11), but given the continuous 
increase in global travel, these isolates may emerge in other 
parts of the world.  
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